Fig. 3From: A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrenceKaplan–Meier estimate of the overall survival for participants assigned to receive observation (blue) or CC-486 (green)Back to article page